Quotient BioResearch Expands Clinical Capacity in Response to Customer Adoption of Its Synthesis-to-Clinic Human ADME Service

Published: May 05, 2011

May 05, 2011 -- Quotient Clinical, a business unit of Quotient Bioresearch (“Quotient”), today announced the completion of a major expansion of its clinical facilities in Nottingham, UK. Bed capacity has been increased by 50 per cent and a dedicated sample processing laboratory for human ADME studies has been incorporated. The new facilities have been inspected and approved for use by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), and have been awarded Supplementary Accreditation.

The expansion is a direct response to increasing customer adoption of Quotient’s Synthesis-to-Clinic™ platform, in particular in support of human ADME studies, and reinforces Quotient’s position as a leading provider of 14C-enabled drug development services including Phase 0 microdose, ivMicrotracerTM, and human metabolism studies.

Synthesis-to-Clinic integrates each component required to undertake a 14C-enabled clinical study into a single supply chain, spanning 14C API radiosynthesis through to the clinical study report. The ability to seamlessly deliver such a program under a single contract, with a single project manager and continuity of scientific input throughout, delivers significant benefits to the drug development project team.

Mark Egerton, MD Quotient Clinical, commented: “In parallel with the recent expansion of our Pharmaceutical Sciences laboratory and GMP drug product manufacturing facility, the completion of this clinical expansion is another milestone in the development of our business. It underlines the strength of our Synthesis-to-Clinic platform and the benefits it brings to our global client base. Our expanded facilities will assist the continued development of our services, supporting our customers in taking new and innovative approaches in early drug development.”

About Quotient Clinical

Quotient Clinical is a leading provider of early clinical development services, and offers a unique streamlined process to reduce the time from First-in-Human studies through to Proof-of-Concept, integrating flexible drug product manufacture into clinical trials through its Translational Pharmaceutics platform.

Its unique RapidFACT service enables the rapid development, manufacture, and clinical evaluation of new drug formulations and addresses the challenge of poorly soluble drugs in early development.

Synthesis-to-Clinic allows provision of 14C clinical studies as a fully integrated service. This platform enables all the different processes involving 14C drug products from, synthesis of the 14C labelled drug molecule through to conduct of human clinical trials to be undertaken with a single vendor and a single project manager throughout. This increases efficiency and delivers significant time and cost savings.

With an existing strong customer base in the United States, Europe and Japan, the principal focus of Quotient Clinical is to provide a unique and comprehensive range of early development to a broad range of pharmaceutical and biotechnology customers. Quotient Clinical is a business unit of Quotient Bioresearch.

About Quotient Bioresearch

Quotient Bioresearch is a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide. The company offers a unique range of drug development services through its three business units – Chemistry and Metabolism, Bioanalytical Sciences and Clinical. Quotient has grown rapidly since 2007 through a combination of both acquisition-led and organic growth.

For further information: www.quotientbioresearch.com

For further information please contact:

Kirsty Roberts

Account Manager

BCS Public Relations

E-mail: kirsty@bcspr.co.uk

Tel: +44(0)115 948 6901

Back to news